Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.62 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.62 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889573 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18387237 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL15354502 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18744496 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL15354496 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18383015 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL890313 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL18726403 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL20361767 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 | |
| SCHEMBL887972 | 1.00 | LGALS8 (0.62) | LGALS8LGALS3LGALS4GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | MIDATECH LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| EP-2579898-B1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH LTD (GB) | 2019-01-09 | — | — | EP | disclosed |
| EP-2717858-B1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | AQUESTIVE THERAPEUTICS INC (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017017063-A2 | NANOPARTICLE-BASED LIVER-TARGETING THERAPY AND IMAGING | MIDATECH LIMITED (GB) | 2017-02-02 | — | — | WO | disclosed |
| EP-2579844-B1 | NANOPARTICLE FILM DELIVERY SYSTEMS | MIDATECH LTD (GB) | 2016-02-24 | — | — | EP | disclosed |
| WO-2012170828-A1 | COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME | MONOSOL RX, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | MIDATECH PHARMA PLC (GB) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171291-A1 | PEPTIDE-CARRYING NANOPARTICLES | CALCA, LNPEP, CLTA | LGALS8 160/4885LGALS3 99/4885LGALS4 134/4885 |
| US-11179474-B1 | Nanoparticle-based liver-targeting therapy and imaging | LGALS1, CA14, CD44 | LGALS8 27/4885LGALS3 6/4885LGALS4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.